- Home
- IGMS vs RGT Comparison
IGMS vs RGT Comparison
Compare IGMS & RGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- RGT
- Stock Information
- Founded
- IGMS 1993
- RGT 1986
- Country
- IGMS United States
- RGT United States
- Employees
- IGMS N/A
- RGT N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- RGT Trusts Except Educational Religious and Charitable
- Sector
- IGMS Health Care
- RGT Finance
- Exchange
- IGMS Nasdaq
- RGT Nasdaq
- Market Cap
- IGMS 81.9M
- RGT 80.2M
- IPO Year
- IGMS 2019
- RGT N/A
- Fundamental
- Price
- IGMS $1.27
- RGT $12.45
- Analyst Decision
- IGMS Hold
- RGT
- Analyst Count
- IGMS 8
- RGT 0
- Target Price
- IGMS $6.00
- RGT N/A
- AVG Volume (30 Days)
- IGMS 1.3M
- RGT 22.4K
- Earning Date
- IGMS 08-13-2025
- RGT 01-01-0001
- Dividend Yield
- IGMS N/A
- RGT 1.43%
- EPS Growth
- IGMS N/A
- RGT N/A
- EPS
- IGMS N/A
- RGT 0.92
- Revenue
- IGMS $2,681,000.00
- RGT N/A
- Revenue This Year
- IGMS $252.44
- RGT N/A
- Revenue Next Year
- IGMS $46.48
- RGT N/A
- P/E Ratio
- IGMS N/A
- RGT $11.42
- Revenue Growth
- IGMS 27.36
- RGT N/A
- 52 Week Low
- IGMS $0.92
- RGT $7.84
- 52 Week High
- IGMS $22.50
- RGT $11.08
- Technical
- Relative Strength Index (RSI)
- IGMS 48.73
- RGT 68.98
- Support Level
- IGMS $1.26
- RGT $12.18
- Resistance Level
- IGMS $1.37
- RGT $12.39
- Average True Range (ATR)
- IGMS 0.03
- RGT 0.10
- MACD
- IGMS -0.01
- RGT -0.01
- Stochastic Oscillator
- IGMS 8.33
- RGT 87.10
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.